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In the majority of children and adolescents with epilepsy, optimal drug therapy adequately controls their condition.
However, among the remaining patients who are still uncontrolled despite mono-, bi- or tri-therapy with chronic
anti-epileptic treatment, a rescue medication is required. In Western Europe, the licensed medications available for
first-line treatment of prolonged acute convulsive seizures (PACS) vary widely, and so comparators for clinical and
economic evaluation are not consistent. No European guidelines currently exist for the treatment of PACS in
children and adolescents and limited evidence is available for the effectiveness of treatments in the community
setting. The authors present cost-effectiveness data for BUCCOLAM® (midazolam oromucosal solution) for the
treatment of PACS in children and adolescents in the context of the treatment pathway in seven European
countries in patients from 6 months to 18 years. For each country, the health economic model consisted of a
decision tree, with decision nodes informed by clinical data and expert opinion obtained via a Delphi methodology.
The events modelled are those associated with a patient experiencing a seizure in the community setting. The model
assessed the likelihood of medication being administered successfully and of seizure cessation. The associated
resource use was also modelled, and ambulance call-outs and hospitalisations were considered. The patient’s quality
of life was estimated by clinicians, who completed a five-level EuroQol five dimensions questionnaire from the
perspective of a child or adolescent suffering a seizure. Despite differences in current therapy, treatment patterns
and healthcare costs in all countries assessed, BUCCOLAM was shown to be cost saving and offered increased
health-related benefits for patients in the treatment of PACS compared with the current local standard of care.
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Even in a relatively homogeneous region such as West-
ern Europe, with similar population demographics and
state-provided healthcare systems, differences in culture,
legislation and financial incentives can mean that the
treatment of patients with the same condition varies be-
tween countries. In some disease areas, the pathway of
care (even the healthcare setting; that is, primary versus
secondary care) may, therefore, differ between countries,
and some drugs may be used routinely in one country
but not be available in another. A consequence of these
variations is that pharmaceutical companies are faced* Correspondence: dlee@bresmed.co.uk
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in any medium, provided the original work is pwith different challenges in persuading health technol-
ogy assessment (HTA) agencies in each country of the
value of their product. In this paper, we consider the ex-
ample of BUCCOLAM (midazolam oromucosal solu-
tion; available from ViroPharma SPRL – BVBA,
Belgium) in the treatment of prolonged, acute, convul-
sive seizures (PACS) in children and adolescents [1].
Across Europe, 130,000 new cases of epilepsy are re-
corded each year among children and adolescents (an in-
cidence rate of 70–80 per 100,000) [2,3]. The incidence
is particularly high during the first year of life, and the
likelihood of developing the condition then decreases
during childhood [3]. Anti-epileptic drug therapy is the
primary treatment for children with epilepsy, with the
aim of preventing seizures [4], and approximately 70% ofpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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[3,5]. However, patients do not always receive optimal
drug therapy and approximately 50–60% of patients with
epilepsy experience breakthrough seizures during the
course of a year, some of whom will require a prescrip-
tion for rescue medication [2]. Children who have se-
vere, symptomatic epilepsy are those who are most
commonly prescribed rescue medication [6].
The longer a seizure continues, the greater the likeli-
hood of pharmacoresistance to termination and a worse
health outcome for the patient, including increased risks
of subsequent prolonged seizure activity, memory defi-
cits and learning difficulties [7,8]. In addition, the impact
on health resources is greater because these patients re-
quire more intensive medical assistance [6,9-11]. The
costs of direct medical care for children with epilepsy
can be very high – a recent study in Germany, for ex-
ample, showed that the mean direct medical cost over
three months was €1,940 for children with non-drug-
resistant seizures and €3,464 for those with drug-
resistant seizures [12]. Prompt treatment with rescue
medication is an important aspect of care for children
experiencing PACS; however, such treatment provides a
particular challenge because these seizures occur pre-
dominantly in the community setting where rescue
medication and trained carers may not always be
available.
A recent study by Anderson et al. noted that the ideal
drug for the treatment of convulsive seizures in paediat-
ric patients would have the following characteristics [8]:
 A rapid onset of action.
 A broad spectrum of efficacy; that is, not restricted
to a particular seizure type or underlying cause.
 A prolonged duration of action.
 Minimal adverse effects.
 A simple and socially acceptable administration
route for both patient and caregiver.
 Easy storage and portability.
In most European countries, no clear guidance is avail-
able for the treatment of PACS outside of the hospital
setting and no clear guidance is provided for caregivers
[13,14].
In Western Europe, the treatment pathways for the
use of rescue medication in the management of PACS
can be broadly categorised into two groups: many con-
tinental European countries primarily advocate the use
of licensed treatments, whereas a number of other coun-
tries primarily employ unlicensed treatments. More spe-
cifically, in Denmark, France, Germany, Italy and Spain
the mainstay of rescue treatment is rectal diazepam,
which was the only licensed treatment for PACS in chil-
dren until recently. In Switzerland and Germany, thereis frequent off-label buccal use of fast dissolving loraze-
pam tablets (as well as rectal diazepam). Countries that
most commonly use unlicensed buccal midazolam in-
clude the UK, Sweden and Norway [13]. A significant
body of evidence now supports buccal midazolam as an
effective and safe first-line therapy for prolonged sei-
zures [8], which avoids the social stigma of rectal
administration.
In September 2011, BUCCOLAM was granted a
Paediatric-Use Marketing Authorisation (PUMA) by the
European Medicines Agency (EMA) [1]. The PUMA ini-
tiative aims to ensure that medicines used to treat chil-
dren are subject to high-quality, ethical research and are
appropriately authorised without subjecting the paediat-
ric population to unnecessary clinical trials [15].
In most European countries, BUCCOLAM is indicated
for the treatment of PACS in infants, toddlers, children
and adolescents (from three months to <18 years). For
infants between three and six months of age, treatment
should be in a hospital setting where monitoring is pos-
sible and resuscitation equipment is available. In
Switzerland, BUCCOLAM is indicated for emergency
treatment of PACS lasting more than five minutes in
children from six months to 18 years. In all European
countries, BUCCOLAM must only be used by parents/
carers where the patient has been diagnosed to have
epilepsy.
This case study of BUCCOLAM provides an inform-
ative illustration of how variation in a treatment pathway
can lead to different HTA considerations for the same
innovative technology.
Methods
Modelling the local treatment pathway
Decision analytic models were constructed to assess the
cost-effectiveness of BUCCOLAM in seven European
countries. The original model was built for an HTA sub-
mission in Scotland [16], and was subsequently adapted
for use in Wales, Germany, France, Spain, Italy and
Switzerland. In the Republic of Ireland, a full decision
analytic model was not required for reimbursement pur-
poses, as BUCCOLAM was accepted following a rapid
review.
Treatment pathway
In the absence of coherent European guidance on the
treatment of PACS in the community, the use of rescue
medication is determined locally and is subject to sub-
stantial variation. In addition to this, information on the
effectiveness of the various rescue medications is not
available, with only limited information available on their
efficacy. This is the result of many products being used
unlicensed or off-label, which is a relatively common
practice in paediatric medicine throughout Europe [17].
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veys and interviews with clinical experts. The numbers
and backgrounds of the participating experts for each
country are shown in Additional file 1: Table S1. Expert
responses were used to determine the local pattern of
care in each jurisdiction and to derive model parameter
estimates. In general, experts were consistent in their es-
timates for parameters used to model hospitalisation and
healthcare resource use. A greater variation was seen in
estimates for events in the community setting, both be-
tween clinicians and by country. This was attributed to
the fact that clinicians rarely directly observe treatment
in the community, resulting in greater uncertainty in
their responses. In Scotland, Wales and Spain, expert
opinion was supplemented with parent surveys to ad-
dress this limitation.
Variation was observed in the treatment pathways of
different countries, particularly concerning the rescue
medication administered by parents and carers following
a seizure in the community setting. The established
treatment practice involved the use of an unlicensed
buccal midazolam preparation in Scotland and Wales,
rectal diazepam in Spain and Italy, and a combination of
rectal diazepam with other licensed and/or off-label or
unlicensed rescue medications in Germany, France and
Switzerland. Differences in paramedic and hospital drug
use were also seen between countries. The establishedTable 1 Medications currently administered in the communit
Country Carer administration Paramedic adminis
Scotland Buccal midazolam 100% Rectal diazepam 100
Wales Buccal midazolam 95% Rectal diazepam 100
Rectal diazepam 5%
Germany Rectal diazepam 81% Rectal diazepam 82%
Buccal use of lorazepam tablets 19% Lorazepam 6%
Clonazepam 6%
Phenytoin 6%
Spain Rectal diazepam 100% Rectal diazepam 100
France Rectal diazepam 92% Rectal diazepam 84%
IV clonazepam 10%Oral clonazepam 8%
Phenytoin 6%
Italy Rectal diazepam 100% Rectal diazepam 10%
IV midazolam 90%
Switzerland Rectal diazepam 45% Rectal diazepam 50%
Buccal lorazepam 54% IV diazepam 6%





‘Buccal midazolam’ in this table refers to the unlicensed preparation.current pattern of treatment formed the comparator
arm of the model for each country and is shown in
Table 1.
Variation was also observed in the treatment practices
used by parents and carers (Table 2). In Wales,
Germany, France and Switzerland, some parents and
carers had instructions from their clinician to administer
a second dose of rescue medication if the first dose
did not stop the seizure. In Germany, France and
Switzerland, patients were not necessarily taken to hos-
pital after an ambulance call-out, with paramedics ad-
ministering medication and often awaiting results before
taking the child to hospital. These differences were in-
corporated into the models to better define the decision
problem for the relevant healthcare system.
Efficacy
No data that specifically evaluate the efficacy of buccal
midazolam in prefilled syringes are currently available.
Five studies comparing the efficacy of buccal midazolam
with that of rectal diazepam have been conducted [8].
The source of efficacy data used within the models was
the study by McIntyre et al. [18]. This is the only pub-
lished controlled trial comparing buccal midazolam (the
intravenous preparation of midazolam hydrochloride,
administered into the buccal cavity) with rectal diaze-
pam that was conducted in a European context with ay, by ambulance paramedics and in hospital
tration Hospital administration Source
% Buccal midazolam 100% Delphi panel and patient surveys
% Buccal midazolam 38% Delphi panel and patient surveys
Rectal diazepam 62%




% Rectal diazepam 100% Delphi panel and patient surveys
Rectal diazepam 84% Delphi panel
IV clonazepam 10%
Phenytoin 6%
Rectal diazepam 65% Delphi panel
IV midazolam 35%
Rectal diazepam 50% Clinician interviews
IV diazepam 6%
IV lorazepam 43%
1% Intranasal midazolam 1%
IV clonazepam <1%
Phenobarbital <1%
Table 2 Key structural characteristics and major treatment pathway differencesa of European cost-effectiveness model
adaptations
Country Model features
Scotland ● Patient simulation for buccal midazolam comparison
● Parents/carers only give a single dose
● Taken to hospital if ambulance called
Wales ● Patient simulation for buccal midazolam comparison
● Allows for second doses of treatment under emergency care plans
● Taken to hospital if ambulance called
● Chance of inpatient admission is 100% for patients suffering multiple seizures
● Additional chance of admission to intensive care for patients suffering multiple seizures
Germany ● Allows for second doses to be administered
● Patient may not necessarily be taken to hospital after ambulance call-out
Spain ● Parents/carers only give a single dose
● Taken to hospital if ambulance called
France ● Allows for second doses to be administered
● Patient may not necessarily be taken to hospital after ambulance call-out
Italy ● Parents/carers only give a single dose
● Taken to hospital if ambulance called
Switzerland ● Allows for second doses to be administered
● Patient may not necessarily be taken to hospital after ambulance call-out
a According to clinician consultation.
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also reported outcomes directly related to resource use
associated with seizures, which is a key contributor to
the expected incremental benefit of BUCCOLAM. Al-
though the trial observed a UK cohort, the comparative
efficacy of buccal midazolam in reducing the duration of
seizures and the probability of repeat seizures is assumed
to be applicable to all the countries considered in this
article.
The following assumptions were made in order to use
the outcomes of the McIntyre publication within the
economic model and estimate the chance of a seizure
lasting more than ten minutes, the chance of a repeat
seizure and the duration of seizures:
 BUCCOLAM (midazolam oromucosal solution) has
equal efficacy to IV midazolam as hydrochloride
5 mg/ml administered by the oromucosal route.
 All other formulations of buccal midazolam and
intranasal midazolam have equal efficacy to IV
midazolam as hydrochloride 5 mg/ml administered
by the oromucosal route.
 Model comparators other than buccal and intranasal
midazolam share the same efficacy outcomes as
rectal diazepam.
These assumptions were based on the advice of clin-
ical experts in several countries. In the case of off-labelmedications, the assumption of equal efficacy with rectal
diazepam was a conservative estimate as clinical experts
in several countries suggested that other off-label medi-
cations, such as lorazepam tablets administered by the
buccal route, were less efficacious than rectal diazepam.
This conclusion is supported by pharmacokinetic
evidence indicating that midazolam is more likely to
achieve therapeutic plasma concentrations than loraze-
pam [8].
Effectiveness
The primary source of effectiveness data used in the
models was clinical expert opinion, which was obtained
through Delphi panel research conducted in a number
of European countries as part of the cost-effectiveness
assessment of BUCCOLAM. The Delphi process in-
volved three rounds: the first consisted of a question-
naire and the second consisted of either a second
questionnaire or a group face-to-face meeting at which
the initial questionnaire results were presented back to
all participants and amended or validated; the final
round provided an opportunity for comment or revision
on the consensus gained in the second round [19].
The Delphi panels reported a number of different ex-
pected advantages for BUCCOLAM compared with each
of the main treatment alternatives used in the commu-
nity. They estimated that BUCCOLAM had both an effi-
cacy and an effectiveness advantage over rectal diazepam
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many cases, that it had an effectiveness advantage com-
pared with unlicensed buccal midazolam. This advantage
in effectiveness could be attributed to BUCCOLAM be-
ing presented in prefilled syringes and, in some coun-
tries, to the additional willingness or ability of carers
(such as teachers) to administer a licensed product via
the oromucosal route, leading to a reduction in ambu-
lance call-outs. The Delphi panels also estimated a re-
duction in wastage costs with BUCCOLAM, due to its
convenient and efficient mode of packaging (BUCCO-
LAM in four prefilled unit-dose syringes versus
unlicensed buccal midazolam for which the most widely
used presentation is a single 10 ml bottle with four
syringes).
These results are supported by a recent survey com-
pleted by a total of 129 healthcare professionals in six
European countries, which indicates that the biggest bar-
rier to administering rescue medication to children suf-
fering PACS in the community is fear of legal
consequences, either due to the use of unlicensed medi-




A decision tree approach was used to reflect the events
during and immediately following PACS. The structure
of this model, which was built in Microsoft Excel, is
shown in Figure 1 [16].
A number of events can trigger an ambulance call-out
in the decision tree; a carer not administering treatment
in the community, failed delivery of treatment by theFigure 1 Structure of decision tree included in all country adaptation
medical advice.carer, a seizure that lasts more than ten minutes or a re-
peat seizure within one hour of the first. Once an ambu-
lance has arrived, paramedics may administer further
treatment, and a patient may be taken to hospital. If a
patient is taken to hospital, patients may receive further
treatment, and may be admitted for a hospital stay.
The decision node probabilities are tailored to accur-
ately represent the pattern of care in each country. The
probabilities of seizure cessation, repeat seizures and the
duration of seizures are based on the relative efficacy of
buccal midazolam compared with rectal diazepam, as re-
ported by McIntyre et al. [18]. The parameterisation of
these decision nodes for each country is shown in
Table 3.
Medication failure can occur in the model for various
reasons, including: no treatment being available at the
location of the seizure; poor absorption from the site of
administration; or incorrect dose measurement. Delphi
panel members and local clinicians were asked to esti-
mate how the availability of a licensed preparation might
affect the likelihood of treatment administration in the
community setting. Experts in all countries agreed that
administration of treatment in the event of a seizure
would be more likely with BUCCOLAM (Table 3). Simi-
larly, it was expected that the risk of administration er-
rors resulting in under- or overdosing would be reduced
with BUCCOLAM compared with many of the treat-
ments comprising current care.
Patient simulation
In the UK, a different amount of wastage is expected for
licensed and unlicensed buccal midazolam supplied
in four-dose bottles. A patient simulation model was,s [16]. * 2nd dose must only be given according to prior






































































































































































































































a Germany, France and Switzerland only; b In the Welsh model, patient who suffered repeat seizures had a 100% probability of hospital admission.
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pattern of patients’ seizures and whether or not rescue
medication is available at the time of seizure, allowing
the calculation of the cost of expected drug wastage over
the time horizon of the model. Further details on the
simulation model used in the UK cost-effectiveness ana-
lysis can be found in Lee et al. [16].
Costs and resource use
Cost data were typically acquired from national refer-
ence price lists for each country, and expert opinion on
the expected resource use following PACS was also ob-
tained. The key resource use and drug costs included in
the models are shown in Table 4. These are all shown in
euros, for ease of comparison.
The price of BUCCOLAM included in each adaptation
of the model was current at the time it was developed.
UK costs have been updated to the most recent cost
data and so differ from those quoted in the HTA sub-
missions in Scotland and Wales. As the price for BUC-
COLAM in Switzerland has not yet been determined,
the price used in the model is the maximum priceallowable under the price referencing rules in
Switzerland and is based on the agreed prices in the ref-
erence countries.
Health-related quality of life
The quality-adjusted life-year (QALY) decrement associ-
ated with PACS was calculated as the product of the
duration of a seizure event and the estimated health-
related utility value during this time. The former was
broken down to represent three phases of a seizure
episode:
 During the seizure
 Postictal period – the period during which the brain
recovers immediately following the seizure
 Recovery period – the time taken for the patient to
recover back to baseline utility.
Due to a paucity of published utility data pertaining to
a child’s health status during a seizure episode, health-
related quality of life (HRQoL) estimates were elicited
from clinical experts The utility values used in the
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the Scottish model. These values were based on the esti-
mates of four UK clinicians, who had been asked to
complete a five-level EuroQol five dimensions (EQ-5D-
5L) questionnaire from the perspective of a child suffer-
ing a seizure. It is neither feasible nor ethical to adminis-
ter a patient reported outcome measure to a child
during or shortly after a seizure. Therefore the methods
established as best practice for capturing HRQoL for
chronic conditions would have been unsuitable for esti-
mating the effect of acute episodes on HRQoL.
Repeating the measurement and valuation exercises
for each country was not feasible; especially as EQ-5D-
5L tariffs were not available for all the countries consid-
ered. To include the appropriate perspective in valuing
the health impact of the intervention for each country,
the UK values were distributed to the local Delphi panel
members and key opinion leaders (KOLs) to adjust and
validate based on their own expertise (Table 5).Table 4 Drug and resource costs by country
Scotland Wales Ger
Reference year 2012–2013 2012–2013 2012
Cost elements
Ambulance cost €317.23 €284.68 €0.0
A&E: admitted patients €141.35 €141.35 €542
A&E: non-admitted patients €113.41 €113.41 €542
Inpatient admission €680.16 €680.16 €403
ICU admission €1,574.28 €1,574.28 €1,1
Drug costs (per dose)
BUCCOLAM b €26.97 c €26.97 c €28.
Rectal diazepam €2.24 €2.24 €5.0
Unlicensed buccal midazolam €30.38 f €30.66g –
Phenytoin – – €6.6
Oral clonazepam – – –
IV clonazepam – – €1.7
Lorazepam tablets – – €0.3
IV midazolam – – –
Intranasal midazolam – – –
Chloral hydrate – – –
Phenobarbital – – –
IV diazepam – – –
IV lorazepam – – –
A&E = accident and emergency; ICU = intensive care unit; IV = intravenous.
a Ambulance costs for Germany set to zero as they are included in aggregated A&E
requirements (e.g. ex factory, public price) and include VAT as appropriate, therefor
average of each of the four strengths available; d At the time of publication, the ap
shown is the maximum price allowable under the price referencing rules in Switzer
e Italian cost of rectal diazepam is zero as this drug is not reimbursed by the Italian
2013 Drug Tariff price plus a sourcing fee for medicines classed as ‘specials’ [21,22].
All costs are presented in Euros, converted on 30/10/12, using the following rates fr
0.82165 Swiss Francs (CHF).The average time taken to recover to baseline HRQoL
differed according to the events that followed the seiz-
ure. Post-seizure events were categorised into the follow-
ing four scenarios:
 There was no need for an ambulance to be called
 An ambulance was called, but the patient was not
admitted to hospital
 The patient was admitted to hospital, but not into
an intensive care unit (ICU)
 The patient was admitted to an ICU.
Following the end of a seizure, it is assumed that the
recovery of utility at the start of the postictal period is
instant, and the recovery back to baseline utility is linear
over the duration of the recovery period.
The duration of the seizure itself was determined
within the model by the treatment received and was
based on the publication by McIntyre et al. [18]: eightmany Spain France Italy Switzerland
–2013 2012–2013 2011–2012 2012 2012
0 a €309.36 €1,120.76 €113.27 €1,217.06
.87 €129.23 – €335.12 –
.87 €111.10 €25.32 €335.12 €6,194.85
.00 €1,616.89 €1,436.21 €1,147.75 €6,194.85
15.00 €2,254.91 €8,980.05 €4,322.30 €15,157.31
54 €17.38 €17.17 €22.65 €39.93 d
8 €0.94 €0.53 €0.00 e €5.27
– – – –
0 – €0.06 – –
– €0.08 – –
0 – €0.79 – €5.29
9 – – – €0.55
– – €4.18 –
– – – €36.51
– – – €1.40
– – – €82.78
– – – €7.20
– – – €2.40
costs; b The drug costs used for BUCCOLAM were defined by local HTA body
e are not comparable between countries; c The drug cost used represents an
proved price for BUCCOLAM in this country has not been agreed – the price
land.
national health service; f Based on May 2013 Drug Tariff [20]; g Based on May
om xe.com currency converter: 1 Euro (EUR) = 0.806579 British Pound (GBP),
Table 5 Utility values and event durations used to calculate QALYs lost to seizures
Utility values Scotland Wales Germany Spain France Italy Switzerland
Proportion of patients
with severe disability
10% 20% 20% 10% 46% 50% 17.5%
Quality of life for patients without severe disabilities
Baseline 0.879 0.920 0.920 0.879 0.879 0.920 0.864
During seizure −0.204 −0.334 −0.334 −0.204 −0.436 −0.334 −0.436
Following seizure – no
ambulance
0.722 0.722 0.722 0.722 0.507 0.722 0.358
Following seizure –
ambulance called
0.100 0.100 0.100 0.100 0.413 0.100 0.336
Quality of life for patients with severe disabilities
Baseline −0.127 −0.127 −0.127 −0.127 −0.001 −0.127 −0.127
During seizure −0.359 −0.359 −0.359 −0.359 −0.516 −0.359 −0.594
Following seizure – no
ambulance
−0.313 −0.313 −0.313 −0.313 −0.230 −0.313 −0.313
Following seizure –
ambulance called























Time to recovery (hours) – where available, the duration of the postictal phase is shown in parentheses
















88.5 120.0 (24.0) 6.0 (2.5) 88.5 12.5 (0.6) 136.5 BUCCOLAM 12.50;
Current care 12.48
(0.6)
QALYs = quality-adjusted life-years.
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cal or intranasal midazolam, and 15 minutes for rectal
diazepam or other rescue medications. The duration of
the postictal and recovery periods in each of these sce-
narios was estimated by the Delphi panel members and
clinicians in each country, to accurately represent the
expected HRQoL impact on the patient.
Both the HRQoL estimates and the expected duration
of seizure events are summarised by country in Table 5.
An additional consideration highlighted by clinical ex-
perts was a subpopulation of children who suffer from a
severe disability as a result of their epilepsy; for these
children, the QALY loss due to a seizure was expected
to be much lower because of their lower baseline
HRQoL. The proportion of patients estimated to have a
severe disability in each country is reported in Table 5,
together with the reduced baseline and event utility im-
plemented for these patients.Model outputs
The primary outputs of the models were the incremental
costs and QALYs associated with implementation of the
licensed BUCCOLAM preparation. All country models
featured an estimate of the expected annual budget im-
pact associated with adopting BUCCOLAM as standard
care. These analyses were informed by national registry
data and estimates provided by local Delphi panel mem-
bers and KOLs.
Results presented within this manuscript are for an
average year, with no discounting being applied.
Deterministic sensitivity analyses
Deterministic sensitivity analyses were performed to as-
sess the robustness of the models to changes in key par-
ameter values. The upper and lower bounds of each
parameter were modelled to calculate the maximum and
minimum incremental cost-effectiveness ratios (ICERs)
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These analyses assess the sensitivity of the models to the
parameter estimates elicited from clinicians and Delphi
panel members, and estimate the direct impact of treat-
ment pathway characteristics on the cost-effectiveness of
BUCCOLAM across countries.Results
Base case results
The base case analysis showed that BUCCOLAM domi-
nated current care, rectal diazepam and unlicensed buc-
cal midazolam in all countries. This dominance over
current care indicates that BUCCOLAM is both less
costly and more beneficial for patients in all of the coun-
tries included in the analyses (Table 6).
Substantial variation in the expected cost savings
resulting from treatment with BUCCOLAM was ob-
served between the different countries. The model for
Scotland resulted in the lowest predicted cost saving and
the smallest expected impact of BUCCOLAM compared
with the unlicensed preparation. The Swiss model pre-
dicted the largest cost saving following the introduction
of BUCCOLAM. This large saving has multiple causes:
first, the clinical experts in Switzerland predicted a large
difference in effectiveness between BUCCOLAM and
rectal diazepam, due to carer unwillingness to adminis-
ter rectal treatments and the ease of delivery of BUCCO-
LAM; second, the resource use costs associated with
ambulance call-outs and hospitalisations were greater
than those for the other countries considered in the ana-
lyses (Table 4); finally, a comparatively high proportion
of individuals experiencing treatment failure were ex-
pected to be admitted as inpatients or to an ICU. In
countries where unlicensed buccal midazolam is the
comparator (Scotland and Wales), the overall cost sav-
ings were lower than in countries that typically use other
rescue medications.
A breakdown of the incremental costs and savings
of adopting BUCCOLAM over the current pattern of
treatment is shown in Table 7. The ambulance costs
and A&E costs for patients who were not admitted
to hospital were zero in both arms of the German
model. The first is because ambulance costs are in-
cluded in the costs of an A&E visit, and the second
because clinical experts clarified that patients would
always be admitted following an A&E visit, either as
an inpatient or to an ICU.Source of incremental benefit
The cost differences associated with adopting BUCCO-
LAM, a licensed oromucosal midazolam preparation, are
dependent on the standard treatment pathway in each
country, especially the type of rescue medication used.Where the comparator is either rectal diazepam or
bucally administered lorazepam tablets, the cost differ-
ences when adopting BUCCOLAM are due to:
 An increase in drug purchase costs compared with
rectal diazepam and bucally administered lorazepam
tablets
 Increased social acceptability – with some countries
also having legislation preventing the administration
of rectal treatments to children by carers (such as
teachers) – leading to a greater willingness/ability to
administer treatment in the community setting
compared with rectal diazepam
 The availability of a licensed treatment, leading to a
greater willingness/ability to administer treatment
and increased confidence in use in the community
setting compared with bucally administered
lorazepam tablets
 A reduction in the likelihood of failed administration
due to a simpler treatment process compared with
rectal diazepam
 Increased efficacy in stopping seizures and
preventing repeat seizures that result in ambulance
call-out compared with rectal diazepam and bucally
administered lorazepam tablets
 A reduction in the duration of seizures and
associated utility decrement compared with rectal
diazepam and bucally administered lorazepam
tablets
Where the comparator is unlicensed buccal midazo-
lam, the cost differences when adopting BUCCOLAM
are due to:
 A reduction in drug costs compared with unlicensed
product tariffs
 Avoidance of drug wastage due to the supply in
prefilled unit-dose syringes rather than stock bot-
tles, which were reported as the most widely
used presentation of unlicensed buccal
midazolam
 A greater willingness and/or ability of parents and
carers to administer treatment in the community
setting due to increased accessibility of rescue
medication at multiple locations
 A reduction in the likelihood of failed administration
due to greater dosing accuracy
By increasing the proportion of patients in the more
favourable decision tree outcomes (that is, avoidance of
ambulance call-outs and hospital admissions), BUCCO-
LAM is expected to reduce the resource use and
HRQoL burdens of PACS, driving the incremental cost-
effectiveness over standard care in all countries.
Table 6 Base case results by country, one-year time horizon
Country Current care Rectal diazepam Unlicensed buccal midazolam BUCCOLAM
Costs QALYs No of ambulance
call-outs
Costs QALYs No of
ambulance call-
outs
Costs QALYs No of ambulance
call-outs
Costs QALYs No of
ambulance call-
outs
Scotland €5,544 0.75030 8.31 €6,997 0.74475 11.45 €5,544 0.75030 8.31 €5,145 0.75112 7.83
Wales €5,019 0.68030 6.23 €7,539 0.67016 9.65 €4,565 0.68231 6.05 €4,412 0.68458 5.87
Germany €13,278 0.69522 12.99 €13,340 0.69520 13.04 N/A € 9,770 0.69662 9.20
Spain €12,862 0.74736 8.34 €12,862 0.74736 8.34 €7,378 0.75543 4.69
France €8,550 0.47491 3.02 €8,550 0.47491 3.02 €5,913 0.47516 2.07
Italy €6,214 0.38552 3.96 €6,214 0.38552 3.96 €4,674 0.38808 2.92
Switzerland €27,174 0.68921 2.99 €28,588 0.68916 3.15 €17,777 0.68957 1.94
Country Incremental versus current care Incremental versus rectal diazepam Incremental versus unlicensed buccal midazolam
Costs QALYs Ambulance call-
outs avoided
ICER Costs QALYs Ambulance call-
outs avoided
ICER Costs QALYs Ambulance call-
outs avoided
ICER
Scotland –€399 0.00082 0.48 Dominant
a
–€1,852 0.00637 3.62 Dominant
a
–€399 0.00082 0.48 Dominant a
Wales –€607 0.00429 0.36 Dominant
a
–€3,127 0.01442 3.79 Dominant
a


































ICER = incremental cost-effectiveness ratio; N/A = not applicable as unlicensed buccal midazolam is not used in these countries; QALY = quality-adjusted life-year.




















Table 7 Breakdown of base case incremental costs of BUCCOLAM versus standard care, one-year time horizon
Costs Scotland Wales Germany Spain France Italy Switzerland
Drug costs –€107.86 –€15.77 €342.99 €133.09 €43.85 €81.03 €138.07
Ambulance costs –€152.05 –€101.44 €0.00 –€1,127.20 -€1,061.04 –€116.98 –€1,279.31
A&E costs (no admission) –€43.48 €29.73 €0.00 –€137.64 -€6.47 –€103.83 -€640.31
Inpatient admission costs –€63.00 –€497.96 –€3,222.80 –€3,779.18 -€550.67 –€918.89 –€4,482.20
ICU admission costs –€32.89 –€21.22 –€627.64 –€573.34 -€1,062.69 –€481.01 –€3,133.39
Total –€399.28 –€606.66 –€3,507.45 –€5,484.26 -€2,637.02 –€1,539.68 –€9,397.13
A&E = accident and emergency; ICU = intensive care unit.
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Table 8 shows an expected budget impact between
€840,808 and €65.8 million per country for the first year
following the introduction of BUCCOLAM.
National epidemiology sources were used to estimate the
patient population; that is, the prevailing number of epi-
lepsy patients who suffer breakthrough seizures and are eli-
gible to receive rescue medication, as well as the expected
number of incident patients each year. Among this patient
population, a given percentage was assumed to take up
BUCCOLAM in the first year following its introduction,
accruing the savings observed in the model (see Table 8).
The estimated total healthcare budget impact was
largely determined by the expected savings per patient,
but was also influenced by the market uptake of BUC-
COLAM, which was estimated at 10–50% in the first
year of availability and was typically expected to rise in
subsequent years.Table 8 The expected annual healthcare budget impact of ad
Scotland Wales
Population aged 0–18 years 2,993,000
Prevalence rate
Absolute prevalence
Proportion receiving rescue medication
Absolute number receiving rescue medication 2,737
Expected one-year mortality a 0.02%
Patients alive to receive treatment a 2,736
Proportion eligible to receive BUCCOLAM
Number of patients eligible 6,820
Market share in first year 50.0% 50.0%
Number of patients transferring from current care
to BUCCOLAM
3,410 1,368
Incremental saving per patientc €399 €607
Total expected savingd €1,361,549 €830,203
a Information on mortality is required in the Welsh health technology assessment s
calculation of the budget impact of BUCCOLAM. For other countries, this was not in
impacted by the rescue medication given.
b In France, it was expected that the number of children being prescribed rescue m
of BUCCOLAM.
c The incremental saving per patient is taken from Table 7 (Breakdown of base case
d The total expected saving is calculated as the product of the incremental saving p
to BUCCOLAM.Sensitivity analyses
Deterministic sensitivity analysis
Figure 2 shows the impact of the three most influential
parameters from each model. BUCCOLAM remained
cost saving for all parameters tested. The Swiss adapta-
tion contained the greatest uncertainty in results, but
also had the greatest expected cost saving.
A large proportion (12/21) of the most influential pa-
rameters was based on estimates from clinical experts
and patient surveys. Other influential parameters in-
cluded unit costs (5/21) and efficacy outcomes (4/21).
Discussion
When assessing the cost-effectiveness of a healthcare
intervention, the potential impact of this intervention
can be more accurately predicted by accounting for in-
consistencies in the treatment delivery pathways and
health service resource use. The aim of this study was toopting BUCCOLAM
Germany Spain France Italy Switzerland
12,662,656 15,226,230 10,831,152 1,469,605
0.45% 0.50% 0.75% 0.45%
57,558 100,000 76,131 81,234 6,680
48.0% 30.0% 96.7%
27,628 22,839 6,457
70% 25% 110% b 80%
19,339 25,000 25,123 5,166
10.0% 48% 17.9% 10.0% 36.7%
1,934 12,000 4,504 8,123 1,894
€3,507 €5,484 €2,637 €1,540 €9,397
€6,783,169 €65,811,104 €11,877,804 €12,507,399 €17,801,274
ubmission template, and this was provided in addition to the base case
cluded, as mortality rates are low and not expected to be substantially
edication would increase over current levels with the availability
incremental costs of BUCCOLAM versus standard care, one-year time horizon).
er patient and the number of patients transferring from current care
Figure 2 Impact of the three most influential parameters on incremental cost saving of BUCCOLAM.
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patterns for PACS on the economic evaluation of BUC-
COLAM. The analysis demonstrated a cost saving with
the introduction of BUCCOLAM in all the countries
evaluated. This was driven by different factors, depend-
ing on the pathway in which the drug was evaluated.
The pathway characteristic that most heavily influ-
enced the potential saving achieved with BUCCOLAM
was the rescue medication currently used in the treat-
ment of PACS. BUCCOLAM was estimated to provide
greater incremental benefit when compared with rectal
diazepam (primarily as a result of increased efficacy and
social acceptability leading to increased use) than com-
pared with an unlicensed preparation of midazolam
(where benefits were limited to drug price differences
and more probable and successful administration by
carers). This meant that the adoption of BUCCOLAM
was of greater value in healthcare systems in which rec-
tal diazepam was standard care.
In addition to the choice of comparator, a number of
other pathway characteristics influenced the degree of
cost saving. These fell into two categories: the value of
reducing healthcare resource use and the procedure by
which PACS are treated. The former is evident when
considering the variation in unit costs, which is ex-
plained by differences in tariffs and other factors, includ-
ing the average length of stay and the staff time
involved; thus, the organisation and delivery of local
healthcare resources impact on the magnitude of the in-
cremental cost of adopting BUCCOLAM. The latter is aresult of the treatment pathway parameters estimated by
the clinical experts. These parameter values are indica-
tive of the treatment provided in each healthcare system;
for example, the criteria that determine the requirement
for hospital admission differ by country, so that patients
with less severe needs might be hospitalised in one
country but not in another. These parameters determine
the likelihood that treatment with BUCCOLAM will
affect the events following a seizure episode and result
in the potential savings from reduced resource use. The
sensitivity analyses performed show that variation in
those parameters heavily impacted the expected savings
achieved with BUCCOLAM, with 12 out of the top 21
influential parameters having been sourced from expert
opinion or patient surveys.
This highlights the sensitivity of the model to the re-
sponses of the Delphi panel and survey participants.
Firstly, it demonstrates how the differences between the
countries impact the outcomes of the model. Secondly,
it illustrates that the method used to elicit parameter
values from clinicians introduces considerable uncer-
tainty into the analyses. However, the results of the de-
terministic analysis suggest that this does not
significantly change the cost-effectiveness outcomes for
BUCCOLAM in the decision problem considered here
(Figure 2).
A patient’s needs upon hospitalisation are likely to fur-
ther affect the unit costs used to model the treatment of
the average patient (less severely ill patients who do not
require as much medical attention will bring down the
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each system, therefore, directly influences both the likeli-
hood and the potential value of successfully treating a
seizure episode in the community and avoiding referral
to secondary care services.
A number of issues, inherent with the episodic nature
of the disease, presented themselves during the con-
struction of the models. While the direct impact of res-
cue medications on stopping a seizure episode can be
observed in a clinical setting (for example, in the study
by McIntyre et al.) [18], the events relevant to the deci-
sion problem take place in the community setting. This
means that obtaining unbiased estimates of how these
events might be influenced by the choice of treatment is
problematic; for example, the sequence of events is ex-
pected to differ according to the cultural context in
which the seizure takes place. These societal aspects of
healthcare provision include the daily routine of the
child, the level of training offered to parents and
teachers, and the inclination (or disinclination) of care-
givers to perform rectal administration. Capturing these
factors accurately in an economic model requires a level
of detail that is difficult to achieve through traditional
data collection methods, particularly given the known
high levels of country-to-country variation in aspects
such as carer training and willingness to administer res-
cue treatments in the community [13,14]. Where param-
eter values have been estimated by proxy, model
outcomes can be confirmed through incorporation of
primary observational data, this work is ongoing as part
of the PERFECT study [13,14].
Another limitation when constructing the models was
the difficulty in obtaining HRQoL values to estimate the
effect of a seizure episode on utility. There will be some
error introduced by the indirect nature of the estimation
of utility values, but it is not clear whether this will
under- or over-estimate patient utility. Although there is
a consensus in published comparisons of utility esti-
mates from patients and proxies that indirect estimates
must be interpreted with caution, the direction of the
error is not consistent [23-25]. Although the derivation
of utility estimates is not ideal, the particular characteris-
tics of this condition and currently available instruments
mean that it is the most appropriate option. As there is
no way of directly measuring utility during a seizure epi-
sode, the only method of eliciting utilities is by proxy, ei-
ther from clinicians or parents. Consequently, the EQ-
5D (designed for people older than 12 years) rather than
the youth version (EQ-5D-Y – designed for children
aged between five and 12 years [26]) has been used. The
only difference in the versions is that the wording in the
youth version has been adapted for younger readers.
Furthermore, standard HRQoL instruments are designed
to evaluate chronic health states and not to capture theHRQoL impact of acute, short-lived episodes, and it is
the QALY loss during seizure episodes that is important
in considering the treatment effect of BUCCOLAM.
Sensitivity analyses examining the influence of utility
estimates suggest that the absolute utility value does not
affect the overall outcome of the model. The incremen-
tal QALY gain with BUCCOLAM is derived from the re-
duced utility decrements associated with the shortened
seizures and recovery times. If the treatment is demon-
strated to reduce the duration and ultimate severity of
the seizure, then the change in QALYs will always be
positive (or zero), regardless of the absolute utility base-
line and the magnitude of the decrement. It may be that
this QALY gain is negligible, but this is simply due to
the short-lived nature of the events and the quality of
life benefit to the patient may be under-represented in
traditional QALY calculations.
The patient population in which BUCCOLAM is indi-
cated presents additional obstacles. A common problem
associated with the economic evaluation of paediatric in-
terventions is the lack of availability of relevant clinical
trial data, due to unwillingness to recruit children into
clinical trials. This results in a reliance on off-label drug
formulations in clinical practice [14]. The problem is
compounded by the authorisation of BUCCOLAM by
the PUMA process, which is designed, in part, to reduce
unnecessary enrolment of children to clinical trials and
reduce the requirement for paediatric-specific data to
obtain a licence. This can result in a paucity of data for
the purposes of reimbursement decisions for the
intended patient population.
The limitations discussed in this section resulted in a
greater reliance on expert opinion, rather than on pub-
lished, peer-reviewed evidence, to construct the models.
This presents a number of technical issues; although cli-
nicians may provide point estimates of key model pa-
rameters, they are much less able to make probabilistic
statements regarding the estimates to be used in sensi-
tivity analyses. The requirement for arbitrary variation
and bounds means that, although probabilistic analysis
can be undertaken, this does not capture fully the struc-
tural uncertainty underlying the model. In addition, the
process used to capture expert opinion was more strin-
gent in some countries than others, with the numbers of
clinicians consulted ranging from four to ten per coun-
try. The results for Switzerland in particular are limited
due to a low number of participating clinicians and an
inability to apply a full Delphi process over three rounds.
However, the consistency of the cost-saving result with
respect to the adoption of BUCCOLAM across the
range of countries evaluated suggests that the results
may be generalisable to other countries within Europe.
The total cost of managing epilepsy was estimated at
€15.5 billion across the 25 EU countries in 2004; this
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medication accounted for only €400 million (approxi-
mately 2.5%) of this total cost, and around 15% of the
direct healthcare costs (removing indirect and non-
medical costs) for epilepsy. As the cost of rescue medi-
cation is comparatively small in relation to the overall
burden of managing epilepsy, determining optimal treat-
ment pathways for PACS is considered a low priority for
appraisal bodies. This is evident in the decision by the
National Institute for Health and Clinical Excellence not
to refer BUCCOLAM for a Single Technology Appraisal.
This manuscript highlights, however, that although the
price and target population of products such as BUC-
COLAM may not be considered significant enough to
warrant a full review of the drug’s cost-effectiveness, the
cost saving impact on the healthcare systems (and there-
fore on budgets) can be substantial.
Conclusions
The results of this evaluation demonstrate that in the
treatment of PACS in the community setting, BUCCO-
LAM is dominant (reduced costs and greater QALYs)
over current care in each of the countries modelled. This
is the case despite differences in the patterns of care,
local costs and substantial data limitations. Comprehen-
sive sensitivity analyses show that model outputs are ro-
bust for all countries.
A key conclusion of the evidence generated for the
model was that the availability of BUCCOLAM prefilled
syringes is likely to increase both the willingness and
ability of parents and carers to administer treatment in
the community. This improves the effectiveness of the
treatment of PACS, resulting in better outcomes compared
with rectal diazepam. As a result of these improved
outcomes, BUCCOLAM was estimated to consistently
reduce ambulance call-out and hospitalisation rates for the
treatment of PACS across a range of healthcare systems.
The capacity for BUCCOLAM to reduce resource use
and expenditure following a seizure episode has been dem-
onstrated across a range of European healthcare systems.
Although the expected savings may be considered small in
relation to the total international economic burden of
treating epilepsy, this does not diminish the improved out-
comes experienced by the individual and the substantial
savings that can be achieved compared with current care.
Additional file
Additional file 1: Table S1. Delphi participants by country.
Competing interests
This study was funded by ViroPharma SPRL-BVBA. ViroPharma is the
manufacturer of BUCCOLAM® (midazolam oromucosal solution). The authors
independently conducted all analyses and wrote the manuscript. The authors
controlled the decision to write and submit the manuscript for publication.Authors’ contributions
The study was designed by DL, AH, NB, AS and ET. The methods were
implemented by DL, DG, JP and AH. DL, DG, AH, NB, AS and ET participated
in the review and interpretation of the data analysis. Delphi Panels were
conducted by AH and NB. The manuscript was written by DL, JP and DG,
and reviewed by AH, AS, NB and ET. DL is the guarantor for the overall
content of this paper. All authors read and approved the final manuscript.Acknowledgements
The authors would like acknowledge the contributions of Julio Bastida of
University Casti lla-La Mancha, Marco Anelli of KeyPharma S.r.l, Stefan Vegter
of Vegter Health Economic Research, Amélie Beaudet of IMS Health, Caroline
Reynaud of JNB-Développement and members of Hayward Medical
Communications.
Author details
1BresMed, North Church House, 84 Queen Street, Sheffield S1 2DW, UK.
2BioExcel, Cornbury Park, Charlbury, Oxfordshire OX7 3EW, UK.
Received: 13 September 2013 Accepted: 10 January 2014
References
1. ViroPharma Limited: BUCCOLAM 2.5 mg oromucosal solution: summary of
product characteristics; 2011. www.medicines.org.uk/emc/medicine/25541/
spc. Accessed 28 March 2014.
2. Forsgren L, Beghi E, Oun A, Sillanpaa M: The epidemiology of epilepsy in
Europe - a systematic review. Eur J Neurol 2005, 12:245–253.
3. SEIN (WHO Collaborating Centre for Research, Training and Treatment in
Epilepsy), W.H., and the ILAE/IBE/WHO Global Campaign Against Epilepsy:
EPILEPSY IN THE WHO EUROPEAN REGION: Fostering Epilepsy Care in Europe.;
2010. www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf. Accessed
28 March 2014.
4. World Health Organization: Epilepsy: Fact Sheet No999; 2012. www.who.int/
mediacentre/factsheets/fs999/en/index.html. Accessed 28 March 2014.
5. Sander JW: The use of antiepileptic drugs–principles and practice.
Epilepsia 2004, 45(Suppl 6):28–34.
6. Klimach VJ: The community use of rescue medication for prolonged
epileptic seizures in children. Seizure 2009, 18:343–346.
7. Pellock JM: Overview: definitions and classifications of seizure
emergencies. J Child Neurol 2007, 22:9S–13S.
8. Anderson M: Buccal midazolam for pediatric convulsive seizures: efficacy,
safety, and patient acceptability. Patient Prefer Adher 2013, 7:27–34.
9. Scott RC, Besag FM, Neville BG: Buccal midazolam and rectal diazepam for
treatment of prolonged seizures in childhood and adolescence: a
randomised trial. Lancet 1999, 353:623–626.
10. Camfield CS, Camfield PR, Smith E, Dooley JM: Home use of rectal
diazepam to prevent status epilepticus in children with convulsive
disorders. J Child Neurol 1989, 4:125–126.
11. O’Dell C, Shinnar S, Ballaban-Gil KR, Hornick M, Sigalova M, Kang H, Moshe
SL: Rectal diazepam gel in the home management of seizures in chil-
dren. Pediatr Neurol 2005, 33:166–172.
12. Riechmann J, Strzelczyk A, Reeses JP, Boor R, Langner C, Neubauer BA,
Obermann B, Philippi H, Rochel M, Seeger J, et al: Direct Costs of Epilepsy
among Children and Adolescents in Germany. Interlaken, Switzerland: 8
Dreiländertagung der Deutschen und Österreichischen Gesellschaften für
Epileptologie sowie der Schweizerischen Liga gegen Epilepsie; 2013.
13. Arzimanoglou A, Lagae L, Cross JH, Beghi E, Mifsud J, Bennett C, Schmidt D,
Wait S, Harvey G: The administration of rescue medication to children
with prolonged acute convulsive seizures in a non-hospital setting: an
exploratory survey of healthcare professionals' perspectives. Eur J Pediatr,
2014. Jan 3. [Epub ahead of print].
14. Wait S, Lagae L, Arzimanoglou A, Beghi E, Bennett C, Cross JH, Mifsud J,
Schmidt D, Harvey G: The administration of rescue medication to children
with prolonged acute convulsive seizures in the community: what
happens in practice? Eur J Paediatr Neurol 2013, 17:14–23.
15. European Medicines Agency: Questions and Answers on the Paediatric Use
Marketing Authorisation (PUMA); 2011. www.ema.europa.eu/docs/en_GB/
document_library/Other/2011/09/WC500112071.pdf. Accessed 28 March
2014.
Lee et al. Health Economics Review 2014, 4:6 Page 15 of 15
http://www.healtheconomicsreview.com/content/4/1/616. Lee D, Gladwell D, Batty AJ, Brereton N, Tate E: The cost effectiveness of
licensed oromucosal midazolam (Buccolam®) for the treatment of
children experiencing acute epileptic seizures: an approach when trial
evidence is limited. Pediatr Drugs 2013, 15:151–162.
17. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C,
Seyberth H, Pandolfini C, Raffaelli MP, et al: Survey of unlicensed and off
label drug use in paediatric wards in European countries. European
Network for Drug Investigation in Children. BMJ 2000, 320:79–82.
18. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B,
Martland T, Berry K, Collier J, Smith S, Choonara I: Safety and efficacy of
buccal midazolam versus rectal diazepam for emergency treatment of
seizures in children: a randomised controlled trial. Lancet 2005,
366:205–210.
19. Hsu CC, Sandford BA: The Delphi technique: making sense of consensus.
Pract Assess Res Eval 2007, 12:1–8.
20. Information Services Division NHS National Services Scotland: Scottish Drug
Tariff May 2013 Section 7S; 2013. www.isdscotland.org/Health-Topics/
Prescribing-and-Medicines/Scottish-Drug-Tariff/Drugs-and-Preparations-with-
Tariff-Prices.asp. Accessed March 28 2014.
21. NHS Business Services Authority NHS: NHS Electronic Drug Tariff: Part IIIB
(May 2013); www.ppa.org.uk/edt/May_2013/mindex.htm. Accessed 28
March 2014.
22. Pharmaceutical Services Negotiating Committee: Unlicensed specials and
imports; 2013. www.psnc.org.uk/publications_download.php/285/
Unlicensed_specials_and_imports_FAQs.pdf. Accessed 13 February 2014.
23. Stephens RJ, Hopwood P, Girling DJ, Machin D: Randomized trials with
quality of life endpoints: are doctors’ ratings of patients’ physical
symptoms interchangeable with patients’ self-ratings? Qual Life Res 1997,
6:225–236.
24. Morrow AM, Hayen A, Quine S, Scheinberg A, Craig JC: A comparison of
doctors’, parents’ and children’s reports of health states and health-
related quality of life in children with chronic conditions. Child: Care,
Health Dev 2012, 38:186–195.
25. Hladschik-Kermer B, Kierner KA, Heck U, Miksovsky A, Reiter B, Zoidl H,
Medicus E, Masel EK, Watzke HH: Patients and staff perceptions of cancer
patients’ quality of life. Eur J Oncol Nurs 2013, 17:70–74.
26. Group EQ: EuroQol – a new facility for the measurement of health-
related quality of life. Health Policy 1990, 16:199–208.
27. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P: Estimating the cost
of epilepsy in Europe: a review with economic modeling. Epilepsia 2007,
48:2224–2233.
doi:10.1186/s13561-014-0006-6
Cite this article as: Lee et al.: A comparison of the cost-effectiveness of
treatment of prolonged acute convulsive epileptic seizures in children
across Europe. Health Economics Review 2014 4:6.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
